Literature DB >> 24475998

Chronic obstructive pulmonary disease in stage I non-small cell lung cancer that underwent anatomic resection: the role of a recurrence promoter.

Chih-Hsi Kuo1, Ching-Yang Wu, Kang-Yun Lee, Shu-Min Lin, Fu-Tsai Chung, Yu-Lun Lo, Chien-Ying Liu, Te-Chih Hsiung, Cheng-Ta Yang, Yi-Cheng Wu.   

Abstract

BACKGROUND: Despite the use of anatomic resection, the post-surgical recurrence rate remains high in early-stage non-small cell lung cancer (NSCLC). Chronic inflammation plays a role in the mechanism that promotes tumor initiation. This study aimed to investigate the association between recurrence outcome and chronic inflammation-related co-morbidities in early-stage resected NSCLC.
METHODS: A review of medical records for recurrence outcome and co-morbidities, in terms of chronic obstructive pulmonary disease (COPD), DM, asthma and cardiovascular diseases, was performed with 181 patients with stage I NSCLC that underwent anatomic resection.
RESULTS: Subjects with T descriptors as T2a disease (49.5 vs. 28.0%, p < 0.05) and the presence of COPD (42.4 vs. 20.7%, p < 0.01) had a higher risk of tumor recurrence. Univariate analysis for recurrence-free survival showed T descriptor as T2a (21.5 months vs. NR, p < 0.05) and the presence of COPD (20.5 months vs. NR, p < 0.01) as significant factors predicting reduced survival. The presence of COPD (HR: 1.98; 95% CI, 1.29-.02, p < 0.01) and T descriptor as T2a (HR: 2.01; 95% CI, 1.04-3.91, p < 0.05) remain independent predictors of reduced recurrence-free survival in the Cox regression model. Patients with COPD were at higher risk of brain recurrence (OR: 7.88; 95% CI, 1.50-41.3, p < 0.01). In contrast, patients without COPD showed a tendency toward recurrence in bone and liver (OR: 4.13; 95% CI, 1.08-15.8, p = 0.05).
CONCLUSION: Subjects with COPD and T2a disease had a higher risk of recurrence. The role of COPD as a recurrence promoter merits further prospective investigation.

Entities:  

Keywords:  COPD; NSCLC; anatomical resection; recurrence

Mesh:

Year:  2014        PMID: 24475998     DOI: 10.3109/15412555.2013.838946

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  9 in total

1.  Recurrence of squamous cell lung carcinoma is associated with the co-presence of reactive lesions in tumor-adjacent bronchial epithelium.

Authors:  Olga V Pankova; Evgeny V Denisov; Anastasia A Ponomaryova; Tatiana S Gerashchenko; Sergey A Tuzikov; Vladimir M Perelmuter
Journal:  Tumour Biol       Date:  2015-10-11

2.  Status of coexisting chronic obstructive pulmonary disease and its clinicopathological features in patients undergoing lung cancer surgery: a cross-sectional study of 3,006 cases.

Authors:  Xiang-Lin Hu; Song-Tao Xu; Xiao-Cen Wang; Dong-Ni Hou; Cui-Cui Chen; Dong Yang; Yuan-Lin Song
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

3.  PGAM5 expression and macrophage signatures in non-small cell lung cancer associated with chronic obstructive pulmonary disease (COPD).

Authors:  F Ng Kee Kwong; A G Nicholson; S Pavlidis; I M Adcock; K F Chung
Journal:  BMC Cancer       Date:  2018-12-10       Impact factor: 4.430

4.  Does chronic obstructive pulmonary disease relate to poor prognosis in patients with lung cancer?: A meta-analysis.

Authors:  Hefeng Lin; Yunlong Lu; Liya Lin; Ke Meng; Junqiang Fan
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

5.  The relationship between chronic obstructive pulmonary disease and non-small cell lung cancer in the elderly.

Authors:  Peng Wang; Min Zhu; Dong Zhang; Xue-Guang Guo; Shu Zhao; Xue-Lin Zhang; De-Long Wang; Chang-Ting Liu
Journal:  Cancer Med       Date:  2019-06-11       Impact factor: 4.452

6.  Impact of coexistent chronic obstructive pulmonary disease on the survival of patients with small cell lung cancer receiving chemotherapy.

Authors:  Sunmi Ju; Hyang Rae Lee; Ju-Young Kim; Ho Cheol Kim; Gyeong-Won Lee; Jung Wan You; Yu Ji Cho; Yi Yeong Jeong; Jong Deog Lee; Seung Jun Lee
Journal:  Thorac Cancer       Date:  2018-08-14       Impact factor: 3.500

7.  Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients.

Authors:  Jeong Uk Lim; Chang Dong Yeo; Chin Kook Rhee; Yong Hyun Kim; Chan Kwon Park; Ju Sang Kim; Jin Woo Kim; Seung Joon Kim; Hyoung Kyu Yoon; Sang Haak Lee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-07-12

8.  Diabetes mellitus and survival of non-small cell lung cancer patients after surgery: A comprehensive systematic review and meta-analysis.

Authors:  Han-Yu Deng; Xi Zheng; Panpan Zha; Lei Peng; Kai-Li Huang; Xiao-Ming Qiu
Journal:  Thorac Cancer       Date:  2019-01-31       Impact factor: 3.500

9.  Impact of coexistent preserved ratio impaired spirometry on the survival of patients with lung cancer: Analysis of data from the Korean Association for Lung Cancer Registry.

Authors:  I Re Heo; Ho Cheol Kim; Seung Jun Lee; Jung-Wan Yoo; Sunmi Ju; Yi Yeong Jeong; Jong Deog Lee; Yu Ji Cho; Jong Hwan Jeong; Manbong Heo; Seung Woo Jung; Tae Hoon Kim
Journal:  Thorac Cancer       Date:  2021-08-01       Impact factor: 3.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.